LDOS — Leidos Holdings, Inc.

Summary of Leidos (LDOS) Q2 2026 Earnings Call

1. Key Financial Results and Metrics

• Revenue: Q2 revenue reached a record $4.6 billion, up 7% year-over-year, with 4% organic growth.
• Adjusted EBITDA: $631 million, maintaining a margin of 13.8%.
• Operating Cash Flow: Nearly $800 million, a record for Q2, with free cash flow of $761 million.
• Book-to-Bill Ratio: 1.1 for the quarter, with Defense segment achieving a 2.2 ratio.
• Earnings Per Share: Non-GAAP diluted EPS increased to $3.26.
• Debt: Total debt at $6 billion with a gross leverage ratio of 2.5x.

2. Strategic Updates and Business Highlights

• NorthStar 2030 Strategy: The strategy is yielding positive results, prompting an increase in revenue and EPS guidance for 2026.
• Defense Segment: Strong performance with accelerated revenue growth and margin expansion. Key contracts include a $1 billion agreement for low-cost munitions and ongoing developments in unmanned systems.
• Health Segment: Strong demand for VBA medical disability exams, although incentive payments have been suspended for the remainder of the year due to administrative reviews by the VA.
• Capital Deployment: Completed a $66 million share repurchase and received a new board authorization for future repurchases.

3. Forward Guidance and Outlook

• Revenue Guidance: Midpoint raised by $100 million; now expecting higher revenue growth despite challenges in the Health segment.
• EPS Guidance: Midpoint raised by $0.05.
• Operating Cash Flow Guidance: Increased by $50 million.
• Defense Growth: Expected to see high single-digit growth, with double-digit growth anticipated excluding the transitioning airborne ISR business.
• Health Segment: Expected to sustain revenues around Q2 levels for the remainder of the year.

4. Bad News, Challenges, or Points of Concern

• Health Segment Challenges: The suspension of incentive payments may impact margins and profitability in the short term. The VA's review process could create uncertainty around future contracts.
• Dependency on Government Contracts: Potential risks associated with government budgeting processes, including continuing resolutions that could affect contract timing and funding.
• Market Conditions: Competitive pressures in the defense sector and the potential for increased in-sourcing by government agencies could limit Leidos' role in systems integration.

5. Notable Q&A Insights

• MHS GENESIS Transition: There is a trend toward in-sourcing by government agencies, which may affect Leidos' traditional systems integration role. However, the company remains confident in its ability to provide value-added services.
• VBA Recompete: The draft RFP for the VBA contract is expected soon, with indications that the current contract will be extended into next year, providing some stability amidst changes.
• Free Cash Flow: Strong performance in Q2 with expectations for continued growth. The company is focused on maintaining low capital intensity while investing in growth areas.
• Defense Opportunities: A robust pipeline of $12 billion in potential contracts, with a focus on unmanned systems and counter-UAS capabilities, indicates strong future growth prospects.

Overall, Leidos reported a strong quarter with solid financial performance and positive strategic developments, despite facing challenges in the Health segment and potential risks from government contracting dynamics.